| 7.13 -1.08 (-13.15%) | 06-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 9.13 |
1-year : | 9.98 |
| Resists | First : | 7.82 |
Second : | 8.55 |
| Pivot price | 7.38 |
|||
| Supports | First : | 6.65 |
Second : | 5.53 |
| MAs | MA(5) : | 7.82 |
MA(20) : | 7.38 |
| MA(100) : | 7.11 |
MA(250) : | 5.88 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 58.9 |
D(3) : | 69.7 |
| RSI | RSI(14): 46 |
|||
| 52-week | High : | 8.73 | Low : | 3.71 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ UNCY ] has closed above bottom band by 36.0%. Bollinger Bands are 49% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 8.41 - 8.45 | 8.45 - 8.49 |
| Low: | 6.67 - 6.71 | 6.71 - 6.74 |
| Close: | 7.07 - 7.13 | 7.13 - 7.18 |
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
Fri, 26 Jun 2026
Unicycive Therapeutics, Inc. Actuals & Estimates (NASDAQ:UNCY) - TradingView
Mon, 22 Jun 2026
Unicycive seeks to distinguish OLC in crowded CKD hyperphosphatemia market - Seeking Alpha
Mon, 22 Jun 2026
Unicycive (UNCY) investors back board slate and 2026 auditor at meeting - Stock Titan
Mon, 15 Jun 2026
Unicycive (NASDAQ: UNCY) CEO receives 762,200 restricted stock units - Stock Titan
Fri, 05 Jun 2026
Unicycive (NASDAQ: UNCY) boosts ATM capacity, files $50M S-3 shelf - Stock Titan
Thu, 21 May 2026
Unicycive Therapeutics: A Catalyst Play With Real Fundamental Upside - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 27 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 2.3 (%) |
| Held by Institutions | 37.6 (%) |
| Shares Short | 2,840 (K) |
| Shares Short P.Month | 2,150 (K) |
| EPS | -2.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.49 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -40.6 % |
| Return on Equity (ttm) | -163.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -29 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -3.17 |
| PEG Ratio | 0 |
| Price to Book value | 4.78 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.82 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|